Pathogenic microorganisms and toxins have evolved a variety of mechanisms to gain access to the host-cell cytosol and thereby exert virulent effects upon the host. One common mechanism of cellular entry requires trafficking to an acidified endosome, which promotes translocation across the host membrane. To identify smallmolecule inhibitors that block this process, a library of 30,000 small molecules was screened for inhibitors of anthrax lethal toxin. Here we report that 4-bromobenzaldehyde N-(2,6-dimethylphenyl)semicarbazone, the most active compound identified in the screen, inhibits intoxication by lethal toxin and blocks the entry of multiple other acid-dependent bacterial toxins and viruses into mammalian cells. This compound, which we named EGA, also delays lysosomal targeting and degradation of the EGF receptor, indicating that it targets host-membrane trafficking. In contrast, EGA does not block endosomal recycling of transferrin, retrograde trafficking of ricin, phagolysosomal trafficking, or phagosome permeabilization by Franciscella tularensis. Furthermore, EGA does not neutralize acidic organelles, demonstrating that its mechanism of action is distinct from pH-raising agents such as ammonium chloride and bafilomycin A1. EGA is a powerful tool for the study of membrane trafficking and represents a class of host-targeted compounds for therapeutic development to treat infectious disease.
T he success of a broad array of microbial pathogens depends on their ability to gain entry into and/or transport proteins into the cytosol of host cells. Intracellular-acting bacterial toxins have evolved to take advantage of numerous host-mediated entry mechanisms (1) , making these toxins ideal tools for studying endocytosis and vesicular trafficking. Indeed, the use of bacterial toxins has contributed to many key discoveries, including membrane recycling, clathrin-independent endocytosis, and retrograde transport (2) . Compounds that inhibit entry of ricin, Shiga toxin, and Pseudomonas aeruginosa exotoxin A (ExoA) into host cells have been identified (3) (4) (5) . These small molecules exhibit varied mechanisms of action, including blockade of retrograde toxin trafficking at the early endosome-trans Golgi network (TGN) junction, morphological disruption of the Golgi apparatus, and inhibition of the toxin active site. Small molecules that disrupt toxin binding, entry, trafficking, and host response can serve not only as probes to dissect such eukaryotic cellular pathways, but also are potential therapeutics for infectious and genetic diseases.
Bacillus anthracis, the causative agent of the disease anthrax, secretes binary toxins that enter host cells and disrupt physiological processes. Lethal factor (LF) is a Zn 2+ -dependent metalloprotease that cleaves mitogen-activated protein kinase kinases (MAPKKs) [1] [2] [3] [4] 6 , and 7 (6, 7) and Nlrp1b (8) (9) (10) and reproduces many pathologies of anthrax when injected into laboratory animals (11, 12) . The cellular entry of LF is dependent on a cell-binding and translocation subunit known as protective antigen (PA). PA is an 83-kDa protein that is cleaved by host proteases into 63-and 20-kDa fragments, allowing oligomerization of the toxin into a prepore (13) . The PA oligomer can then bind up to four monomers of LF, forming a holotoxin complex (14, 15) . Two cellular toxin receptors, TEM8 and CMG2, mediate toxin binding and endocytic uptake (16, 17) . Acidification of the lumen of the late endosome drives a conformational change in the prepore, resulting in insertion into the endosomal membrane and translocation of LF into the cytosol (18) (19) (20) . Alternatively, LF may be translocated to the interior of intraluminal vesicles and transported to the late endosome via multivesicular bodies in a process dependent on COPI and ALIX (21) . The vesicular membranes then fuse with the limiting endosomal membrane and thereby deliver LF to the cytosol (21) .
Despite substantial effort to define binding and entry mechanisms used by lethal toxin (LT), much is still unknown about how it, and indeed many other toxins and viruses, gain access to the host cytosol. To address this, we performed a high-throughput screen to identify small molecules that block cellular entry of LT. Here, we report the identification and characterization of a compound that blocks trafficking of various toxins and viruses to acidified endosomes.
Results
High-Throughput Screen Identifies Potent Anthrax Toxin Inhibitor. To identify inhibitors of toxin entry, we used a cellular intoxication
Significance
Bacterial and viral infections are a significant public health burden. To corrupt normal host cellular functions, many bacterial toxins and all viruses must gain entry to host cells, a process that exploits the host's own cellular machinery. In this study, we use high-throughput technologies to screen for chemical inhibitors of bacterial toxin and viral entry. We report the discovery of a small molecule that inhibits several viruses and bacterial toxins. In addition to the therapeutic potential, this compound represents a powerful probe for dissecting the mechanisms of mammalian membrane trafficking processes.
assay using an immortalized macrophage cell line that undergoes a rapid cell death known as pyroptosis in response to anthrax LT. Pyroptosis is a proinflammatory, caspase-1-dependent cell death that occurs in response to LT in macrophages and dendritic cells encoding certain alleles of the inflammasome gene Nlrp1b (22) . This rapid cytolytic response occurs within 2-3 h of toxin addition and provides a convenient assay for toxin entry. A total of 30,000 small molecules from a commercially available compound library were screened for their ability to inhibit LT-mediated cytotoxicity. Hits were defined based on percentage of survival relative to untreated controls. All compounds that yielded survival greater than 7% (∼0.1% hit rate) were selected for initial revalidation. Thirty-seven initial hits were picked from the source library, assembled onto a single master plate, and retested for protection in the LT macrophage cytotoxicity assay. Compounds that increased survival at least three SDs above controls treated with LT and vehicle were considered verified. Thirty-two compounds exhibited activity in validation assays, whereas five failed to reconfirm. Of the 32 confirmed hits, fresh powder stocks were ordered for 8 compounds, including the 5 that displayed the highest level of protection from LT. Six of these yielded calculable IC 50 values in the macrophage cytotoxicity assay (Fig. 1A and Fig. S1A ), and the other two compounds showed no activity.
The most potent of the validated compounds, 4-bromobenzaldehyde N-(2,6-dimethylphenyl)semicarbazone, which we called EGA, rescued viability to up to 100% of unintoxicated controls with an IC 50 of 1.7 μM (Fig. 1 A and B and Fig. S1 A and B). EGA could be added up to 15 min after LT and still protect cells from killing (Fig. 1C) , suggesting that this compound acts after toxin binding to host cells but at a step early in intoxication.
To determine if the effect of EGA extended beyond established cell lines, primary bone marrow-derived macrophages (BMDMs) from mice with an LT-sensitive Nlrp1b transgene were intoxicated in the presence or absence of EGA. Whereas BMDMs treated with DMSO vehicle were killed efficiently by LT, BMDMs treated with EGA were protected (Fig. 1D) .
NMR and liquid chromatography-mass spectrometry (LC-MS) analysis confirmed purity and structure of commercial EGA ( Fig.  S2 A and B) , reducing the possibility that the activity of EGA is due to a contaminant from its synthesis and/or from a breakdown product. Resynthesis of EGA yielded similar activity as that obtained from the commercial source (Fig. S2C) , further validating the identity of the compound. As an initial investigation of the structure-activity relationship, a series of related compounds from Chembridge was assayed. Interestingly, none of the commercially available EGA analogs were active ( Fig. 2 and Fig. S3 ). These compounds revealed critical roles for four-position substitution on the benzaldehyde, as well as 2,6 substitutions on the aniline ring. Furthermore, the semicarbazone linker appeared to contribute to compound activity.
EGA Inhibits Cytosolic Entry of LF. To identify the step at which EGA blocks LT-mediated cytotoxicity, processes involved in cellular entry and pyroptosis were assessed in the presence and absence of this compound. Caspase-1 activation, which occurs late in LT intoxication, can be monitored using a fluorescent probe, FLICA, which specifically binds to active caspase-1. Although vehicle-treated controls showed high levels of caspase-1 activity upon LT treatment, active caspase-1 was not detected in EGA-treated cells challenged with LT (Fig. 3A) . This result indicates that EGA blocks intoxication upstream of caspase-1 activation.
Activation of caspase-1 by LT is a late step in pyroptosis and depends on the activity of the proteasome, lysosomal membrane permeabilization, and LF catalytic activity (10, (23) (24) (25) . To determine if EGA blocks a step upstream of LF proteolysis of MAPKKs, we assessed cleavage of MEK2 by immunoblot. Whereas LT cleaved MEK2 in vehicle-treated controls in both RAW264.7 cells and toxin-sensitive BMDMs, treatment with EGA completely abrogated this effect (Fig. 3B) . EGA-treated cells were also found to be resistant to treatment with PA + LFnDTA, a chimeric protein that delivers the catalytic diphtheria toxin A chain to the cytosol in a PA-dependent fashion ( Fig. S4) (26) . Because LF induces pyroptosis and diphtheria toxin induces apoptosis due to inhibition of protein synthesis, inhibitors blocking both could affect some shared mechanism of internalization. These data, combined with the caspase-1 and MEK2 data, strongly suggest that EGA interferes with PAmediated toxin entry.
In order for LF to reach the cytosol, PA 83 must be proteolytically activated to PA 63 , oligomerize into a prepore form, bind LF, and traffic to a low-pH endosome where it undergoes an acid-dependent conformational change from prepore to pore (18) (19) (20) . Host-cell binding, proteolytic processing, and pore formation were monitored by immunoblot in the presence and absence of EGA. Specifically, the pore form of PA resulting from exposure to acidified endosomes is resistant to dissociation by SDS and runs as an oligomer on SDS/PAGE, whereas immature prepores formed by PA 63 are dissociated by SDS and run as monomers (20) . EGA completely inhibited formation of the SDS-resistant oligomer but did not block binding of PA 83 to cells or proteolytic processing to generate PA 63 (Fig. 3C) . The effective dose range for EGA inhibition of oligomer formation (Fig. 3D) closely mirrored the IC 50 in the toxicity assay (Fig. 1) . These results indicate that EGA blocks intoxication at a step downstream of toxin assembly on the host-cell surface but upstream of trafficking to acidified endosomes. BMDMs from two independent mice bearing LT-sensitive alleles of Nlrp1b were treated with a dose titration of EGA followed by LT or media for 3 h, after which viability was measured as above. Averages and SDs were calculated independently from technical triplicates for each mouse.
Impact of EGA on Endosomal Trafficking. Neutralization of acidic compartments by lysosomotropic agents like NH 4 Cl is a wellestablished technique for blocking anthrax toxin entry (27, 28) . The observed block to pore formation raised the possibility that EGA functions by neutralizing low-pH-dependent steps in the endocytic pathway. To address this possibility, Lysotracker Red DND-99 was used to probe acidic compartments in the cell. Lysotracker is a red-fluorescent dye used for tracking acidic organelles in the cell, and neutralization of these compartments can be visualized as a loss in punctate, red-fluorescent structures. Ammonium chloride and bafilomycin A1, a specific inhibitor of vacuolar-type H + -ATPases, markedly decreased cell-associated Lysotracker Red fluorescence (Fig. 3E) . EGA, on the other hand, did not reduce Lysotracker Red signal at concentrations that fully protected cells from LT. These results suggest that EGA blocks the ability of PA to access acidified endosomes but does not function by neutralizing acidic compartments.
We next considered whether EGA-mediated inhibition of endosomal trafficking extended beyond anthrax toxin-receptor interactions by examining trafficking of the epidermal growth factor receptor (EGFR). HeLa cells were treated with epidermal growth factor (EGF), and the stability of EGFR was measured by immunoblotting. At the high dose of EGF used in these experiments (100 ng/mL), EGFR is trafficked to lysosomes and degraded (29) . Lysosomal degradation of EGFR depends on the acidic luminal pH, and lysosomotropic agents such as NH 4 Cl inhibit EGF-induced receptor degradation ( Fig. 4A) (30) . Unlike NH 4 Cl, EGA treatment did not stabilize EGFR at 60 min. EGA treatment did slow degradation somewhat, however, with significantly less EGFR degraded at 30 min post-EGF stimulation (P < 0.05) (Fig. 4B ). This suggested that EGA inhibits trafficking, but that this inhibition can be overcome by excess ligand stimulation over longer periods of time. To test this, we determined the ability of EGA to block lysosomal degradation induced by a lower dose of EGF (20 ng/mL). We used fluorescently labeled EGF to visualize EGFR trafficking and degradation microscopically. EGA treatment stabilized the EGF signal at 60 min, compared with vehicle (DMSO)-treated controls (Fig. 4C) . Notably, EGA treatment also resulted in EGF being retained in enlarged endosomes that stained positive for the early endosome marker EEA1 (Fig. 4C ). These findings indicated that EGA does not block initial binding or endocytic uptake from the plasma membrane, but does inhibit trafficking from early to late endosomes. Fig. 2 . Structure-activity relationship for EGA. EGA and commercially available structural analogs were tested for ability to inhibit LT-mediated cytotoxicity. RAW264.7 cells were seeded at 2 × 10 3 cells/well on 384-well plates and the following day were incubated with indicated doses of (A) EGA [4- 
, and (D) 4-chlorobenzaldehyde N-phenylsemicarbazone (5191420) for 1 h, followed by intoxication with 500 ng/mL PA + 500 ng/mL LF. Cell viability was measured 24 h later as in Fig. 1 . Average values ±SD from technical replicates in a single representative experiment shown. RAW264.7 cells were incubated with EGA or DMSO for 1 h before addition of vehicle control or 231 ng/mL PA + 33 ng/mL LF for 2.5 h. Cells were lysed and analyzed via immunoblotting with a MEK-2-specific antibody. Tubulin was used as a loading control. (C) EGA inhibits PA pore formation. RAW264.7 cells were incubated with 25 μM EGA for 1 h before addition of 400 ng/mL PA for an additional 1 h. Cells were lysed with 1% Nonidet P-40 buffer and analyzed by immunoblotting with a PA-specific antibody. (D) EGA inhibits PA pore formation in a dose-dependent manner. RAW264.7 cells were incubated with a dose titration of EGA for 1 h before addition of 400 ng/mL PA for an additional 1 h. Cells were lysed and analyzed as in C. (E) EGA does not neutralize acidic vessicles. HeLa cells were treated with compounds or vehicle control for 25 min at 37°C before addition of Lysotracker Red (LTR) and Hoechst 33342 for a further 10 min. Cells were imaged by automated fluorescent microscopy, and images were scored for number of LTR-positive structures per cell. Results shown in B-E are representative of at least three independent experiments.
To determine whether other vesicular trafficking events were blocked by EGA, we tested the effect of this compound on phagocytosis and phagolysosomal trafficking. Neither EGA nor bafilomycin A1 inhibited fusion of latex bead-containing phagosomes with lysosomes that had been prelabeled with Texas-red dextran in human monocytic cells (Fig. 4D) . To extend this experiment to bacterial pathogens, we asked whether EGA affects phagocytosis and trafficking of Franciscella tularensis, a Gramnegative pathogen that causes the potentially deadly disease tularemia in humans. Neither EGA nor bafilomycin A1 blocked phagocytic uptake of a live vaccine strain (LVS) of F. tularensis (Fig. 4E ). Furthermore, EGA had no effect on F. tularensis permeabilizatoin of its phagosome as determined by accessibility of LVS to antibody staining in digitonin-treated cells (Fig. 4F ) (31) (32) (33) . In contrast, escape was inhibited by bafilomycin A1 in the time frame of this assay. Therefore, although EGA blocks trafficking of PA to acidified endosomes, this compound does not inhibit phagocytic uptake, trafficking of endosomes to phagocytic compartments, or phagosome maturation required for escape of F. tularensis.
To further elucidate the specificity of EGA, we assessed the effect of this compound on endosome recycling using fluorescently labeled transferrin (Tf), which binds the Tf receptor (TFRC). Like the anthrax toxin receptor (ANTXR), TFRC is taken up by clathrin-mediated endocytosis upon binding its ligand. TFRC releases its iron cargo into the lumen of early endosomes, and then the iron-free Tf-TFRC complex is recycled back to the cell surface through a Rab11-dependent process (34) . EGA had no effect on the amount of Tf recycled back to the surface of cells by 10 and 25 min post-binding (Fig. 4G) , indicating that this compound does not affect endosomal uptake or recycling.
EGA Inhibits Entry of pH-Dependent Bacterial Toxins. Several bacterial toxins and viruses are known to share similar entry requirements with LT, including trafficking to an acidified endosome. Two such toxins, P. aeruginosa ExoA and diphtheria toxin (DT) affect cells by ADP ribosylating EF-2, thereby halting protein synthesis (35) (36) (37) (38) . In contrast, the plant toxin ricin does not require trafficking to acidified endosomes. Ricin is an N-glycosylase that modifies the 28S rRNA of the eukaryotic ribosome and thereby inhibits translation. Unlike the three previously mentioned toxins, ricin is transported in a retrograde fashion to the endoplasmic reticulum (ER) and retrotranslocated into the cytosol by the host ER-associated degradation pathway (2). EGA effectively pro- tected HeLa cells from DT and ExoA (Fig. 5A) . In contrast, cytotoxicity mediated by ricin was not blocked by EGA (Fig. 5B) . These data support the hypothesis that EGA inhibits the entry of toxins that require acidified endosomes. Based on the observation that EGA blocks entry of toxins that require trafficking to acidified endosomes, we next asked whether we could use this inhibitor to characterize entry pathways for toxins that are less well studied. Cytolethal distending toxins (CDTs) are produced by multiple human pathogens, where they promote invasiveness and/or persistence (39) . CDTs are tripartite AB toxins consisting of a single catalytic domain, CdtB, and two cell-binding domains, CdtA and CdtC. CdtB is ultimately trafficked to the host nucleus where it acts as a DNase, triggering DNA damage response, cell-cycle arrest, and apoptosis (40) . Studies on CDT from Haemophilus ducreyi (Hd-CDT) indicate that this toxin, unlike ricin, traffics through acidified endosomes in addition to retrograde trafficking through Golgi and ER (41, 42) . However, CDTs from other pathogens have distinct host factors for binding and entry (42) (43) (44) , indicating that entry pathways used by various CDTs may be idiosyncratic to each. To test this, we determined the ability of EGA to inhibit intoxication by Hd-CDT as well as CDT derived from Escherichia coli (Ec-CDT). As expected, EGA inhibited Hd-CDT-mediated cytotoxicity (Fig. 5C ). Interestingly, EGA did not inhibit intoxication by Ec-CDT (Fig. 5C ), supporting the recent conclusion that these related toxins enter cells through distinct trafficking pathways (42) . Consistent with the EGA-mediated accumulation of EGF in EEA1-positive compartments, Hd-CDT, but not Ec-CDT, was found to accumulate in enlarged vesicles that were EEA1-positive (Fig. 5D ). These data, along with the lack of inhibition of phagocytosis and recycling, support the model that EGA targets a specific subset of vesicular trafficking pathways.
EGA Inhibits Entry of pH-Dependent Viruses. Upon ascertaining that EGA protects cells from several bacterial toxins, we hypothesized that EGA might also be able to inhibit viral entry. Influenza A virus, lymphocytic choriomeningitis virus (LCMV), and vesicular stomatitis virus (VSV), among others, require low pH for membrane fusion and infection of host cells (45) (46) (47) . Distinct from these, amphotropic murine leukemia virus (A-MLV) and Nipah virus (NiV) both enter the cell in a pH-independent fashion (48, 49) .
To test EGA-mediated inhibition of viral entry, we compared transduction by lentiviral vectors pseudotyped with NiV-and VSV-envelope glycoproteins in a cell culture model. The lentiviral genome used encodes green fluorescent protein (GFP), and successful transduction of the host cell results in expression of GFP in the cytosol. EGA effectively inhibited infection of HeLa cells by the low-pH-dependent VSV-pseudotyped lentivirus (Fig.  6A ), but did not inhibit infection of cells by the pH-independent NiV-pseudotyped lentivirus (Fig. 6B) .
The finding that EGA inhibits infection by VSV envelope glycoprotein (VSV-G)-pseudotyped lentiviruses encouraged us to assess its activity on infection by other viruses. We asked whether EGA could inhibit infection by A-MLV as well as by two human pathogens, LCMV and influenza. As expected, infection by A-MLV was not inhibited by EGA, as determined by GFP expression (Fig. 6C) . As a control, we found that the same MLV core was neutralized when pseudotyped with VSV-G (Fig. 6D) . LCMV is a rodent-borne virus that causes meningitis and encephalitis in humans and the prototypical member of the Arenaviridae, a family of viruses responsible for severe hemorrhagic fevers in humans. To determine if EGA affected LCMV multiplication, Vero cells were infected with serial dilutions of a recombinant GFP-expressing LCMV (Armstrong strain) (50) . EGA decreased the total number of cells infected at 2 d after infection as determined by GFP expression (Fig. 6E) . Next, we investigated the effect of EGA on infection by the A/WSN/33 strain of influenza virus. Both LCMV and influenza virus are single-stranded, enveloped RNA viruses, but influenza virus belongs to the Orthomyxoviridae family rather than the Arenaviridae. To assess the effect of EGA on influenza virus infection, HeLa cells were transfected with a luciferase reporter responsive to the influenza polymerase complex. This assay can determine if infection by influenza virus is inhibited at any step up to the translation of viral proteins. Ribavirin and oseltamivir were used as controls. Ribavirin, an antiviral drug that blocks viral RNA synthesis, inhibits influenza and arenavirus infections and is the only licensed drug for treatment of arenavirus infection (51) . Oseltamivir is a neuraminidase inhibitor that blocks influenza viral budding downstream of reporter activation (52) . As expected, ribavirin effectively blocked reporter activation when added 1 h postinfection, whereas oseltamivir exhibited no protection. EGA completely inhibited infection when added 1 h before or simultaneously with virus and even exhibited partial protection when added 1 h post-infection (Fig. 6F) . Although EGA and ribavirin are active against both LCMV and influenza, their differential kinetics, along with the known mechanism of action of ribavirin, suggest that EGA targets a different process in the viral life cycle (53, 54) .
In total, these data show that EGA inhibits cellular infection by multiple viruses, including two medically relevant human pathogens, influenza virus and LCMV. On the other hand, EGA did not block infection by NiV or A-MLV, indicating that it is a specific inhibitor of a subset of viruses that traffic to acidified endosomes.
Discussion
Here we report the use of high-throughput screening to identify a small molecule, EGA, that blocks cellular entry of bacterial toxins and viruses that require trafficking to acidified endosomes. This high-throughput screen leveraged the rapid cytolysis caused by LT in a subset of monocyte-derived cells from certain inbred strains of rodents. However, Nlrp1b-dependent cytolysis is a host-mediated protective response to LT rather than a mechanism of virulence (55) . As such, it is necessary to carefully define the utility of the macrophage cytotoxicity assay and clarify the range of processes that could be affected. Inhibitors that act downstream of LF delivery to the cytosol would be most useful in investigating mechanisms of inflammasome activation, although they would not be predicted to be therapeutically relevant for anthrax. On the other hand, probing processes required for PAmediated toxin entry is predicted to yield agents with therapeutic potential. A subset of the probes that block PA-mediated internalization are likely to interfere more generally with host endocytic processes, which, as described here, may expand their therapeutic relevance to other bacterial toxins and viruses and make them valuable chemical probes for studying host vesicular trafficking.
Indeed, despite the importance of endosomal trafficking in a myriad of cellular events, there is currently a dearth of chemical probes to study these processes. Dynamin-and clathrindependent events are blocked by dynasore and pitstop-1 and -2, respectively (56, 57) . Arf1-dependent trafficking between ER and Golgi is blocked by Brefeldin-A (58). Finally, high-throughput screening for inhibitors of retrograde-trafficking toxins has resulted in identification of a small number of probes with unknown cellular targets (3, 5) . Currently, investigation into the role of numerous other trafficking events relies on inhibitors that target trafficking indirectly, such as lysosomotropic drugs (i.e., bafilomycin A1, NH 4 Cl, chloroquine, ionomycin, nigericin, monensin, etc.) or compounds that target multiple cellular processes in addition to blocking trafficking such as kinase inhibitors (i.e., staurosporine, calphostin C, genistein), phosphatase inhibitors (i.e., okadaic acid, orthovanadate), actin and microtubule inhibitors (i.e., jasplakinolide, latrunculin A, nocodazole, taxol), the HSP90 inhibitor geldanamycin (59), and cholesterol depletion (i.e., cyclodextrins, nystatin) (60) . More specific inhibition of host proteins involved in trafficking can sometimes be achieved by overexpression of dominant negative or constitutively active versions of host proteins, i.e., Rab GTPases or RNAi-mediated knockdown. Although powerful, these approaches are limited to cells that are readily transfectable and are susceptible to compensatory mechanisms that may arise over the longer time course required to establish heterologous expression or knockdown.
The specific cellular target of EGA is currently unknown, but data presented here strongly suggest that the mechanism of action is through inhibition of trafficking between early and late endosomes. The requirement for low pH found in late endosomes is a characteristic shared by toxins, viruses, and natural receptor/li- gand pairs such as EGFR/EGF, which were blocked by EGA. Many of the known inhibitors of LT target this step by directly neutralizing endosomal pH (27, 28) . However, EGA does not block acidification of endosomes as determined by Lysotracker red staining (Fig. 4 A and B) . Furthermore, EGA treatment caused an accumulation of EGF and Hd-CDT in enlarged endosomes that were positive for the early endosome marker EEA1 (Figs. 4C and  5C ). Generation of enlarged EEA1-positive vesicles is also seen when overexpressing a constitutively active form of Rab5 (61), consistent with maturation/trafficking between early and late endosomes as a target for EGA. Importantly, recycling endocytosis of TFRC, phagocytosis of polystyrene beads and live bacteria, and retrograde trafficking of ricin and Ec-CDT were all unaffected by EGA, indicating that this compound inhibits a specific trafficking event.
EGA is an aryl semicarabazone with structural similarity to compounds developed as anticonvulsive agents (62) . The molecular target for anticonvulsive semicarbazones is unknown, but these drugs are thought to function by altering levels of the neurotransmitter GABA (62) . It is possible that EGA shares a molecular target with anticonvulsive aryl semicarbazones, although the high degree of specificity observed in initial structure-activity relationship studies suggests that EGA may have unique target(s) (Fig. 2) . Indeed, one of the most active anticonvulsive aryl semicarbazones, benzaldehyde N-(2,6-dimethylphenyl)semicarbazone (62), showed almost no activity against LT (Fig. 2) . EGA is a potent small molecule for studying vesicular trafficking and represents a class of host-targeted inhibitors that may be developed as therapeutics to treat bacterial and viral disease.
Materials and Methods
Reagents. PA and LF were expressed and purified as described previously (55) . LF N DTA (a fusion of the amino terminus of LF with the diphtheria toxin A chain) was a gift from Jeremy Mogridge (University of Toronto). DT and Pseudomonas ExoA were purchased from List Biological Laboratories. Ricin, bafilomycin A1, and anti-β-tubulin antibody were purchased from Sigma Aldrich. Anti-PA rabbit serum was obtained from Covance. Anti-MEK-2 N-terminal antibody was purchased from Santa Cruz Biotechnology. Horseradish peroxidase (HRP)-conjugated anti-rabbit antibody was obtained from Invitrogen. HRP-conjugated anti-mouse antibody was purchased from AnaSpec. The compound library was from ChemBridge (DiverSet E) and made available through the Molecular Screening Shared Resource at the University of California at Los Angeles. Working stock solutions of compounds were 1-mM compound in DMSO and were stored in sealed 384-well plates at room temperature in dessicated chambers.
High-Throughput Screen. RAW 264.7 macrophages were cultured in complete growth medium consisting of DMEM containing 10% (vol/vol) FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 6.25 mM Hepes, and 1× GlutaMAX-1 supplement (Invitrogen). Two thousand cells were added to each well of the 384-well white polystyrene plates (Matrix) in a volume of 40 μL per well. The cells were allowed to grow overnight at 37°C, 5% CO 2 . The following day, 0.5 μL of 1-mM compound in DMSO was pin-transferred onto cells with a Biomek FX (Beckman Coulter) and custom 500-nL pin transfer tool (V&P Scientific) to achieve a 12-μM final concentration of each compound per well. Cells were incubated with compound for 1 h at 37°C, 5% CO 2 , and then challenged with LT by adding 15 μL of 1.4 × 10 −9 M LF and 1.0 × 10 −8 M PA dissolved in complete growth medium to achieve final concentrations of 3.7 × 10 −10 M LF and 2.8 × 10 −9 M PA. Assay plates were incubated at 37°C, 5% CO 2 , for 20 h and then removed from the incubator, de-lidded, and allowed to cool to room temperature for 1 h. Twenty microliters of ATPlite reagent (Perkin-Elmer) was added to each well. Luminescence values were then measured with the Victor 3 V reader (Perkin-Elmer).
MEK2 Cleavage Assay. MEK2 cleavage assay was performed as described previously with minimal modification (28) . Briefly, six-well plates were seeded with 2 × 10 6 RAW 264.7 cells per well and allowed to grow overnight. Cells were then treated with 231 ng/mL PA and 33 ng/mL LF in the presence or absence of compound at 37°C for ∼2.5 h, washed with cold PBS, and lysed with MCF-7 lysis buffer supplemented with a complete mini protease inhibitor tablet (Roche). Ten micrograms of each protein sample was subjected to SDS/PAGE and immunoblotting with anti-N-terminal MEK-2 antibody, HRP-conjugated anti-mouse HRP secondary antibody, and detected by Immun-Star HRP detection reagent (Bio-Rad).
Caspase-1 Activation. BMDMs from mice expressing transgenic for the LTsensitive 129S1 allele of Nlrp1b were isolated and cultured as previously described (25) . Briefly, femur exudates from two C57BL/6 or two C57BL/ 6 Nlrp1b(129S1) transgenic animals were cultured for 7 d in DMEM (Cellgro, Mediatech, Inc.) supplemented with 10% (vol/vol) FBS (Atlanta Biologicals), 1% penicillin/streptomycin/glutamine (PSG; Gibco), and 2% (vol/vol) 14-22 conditioned media and incubated in a 5% CO 2 humidified incubator at 37°C. Twenty thousand BMDMs from each of the four animals were plated in DMEM supplemented with 10% (vol/vol) FBS and 1% PSG. The following day, cells were treated with 20 μM EGA for 1 h before addition of LT for a further 2 h. FLICA reagent (Immunochemistry Technologies) was added for 1 h and then nuclei were stained with Hoechst 33342. Plates were imaged using an ImageXpress micro automated high content screening system (Molecular Devices), and images were analyzed with MetaXpress software (Molecular Devices).
PA Pore Formation. Six-well plates were seeded with 1.8 × 10 6 RAW 264.7 cells per well and allowed to grow overnight. Cells were preincubated with EGA at indicated concentrations for 1 h before PA binding (400 ng/mL) for 1 h at 37°C, at which time samples were washed with cold PBS and harvested as described previously. Protein samples were subjected to SDS/PAGE and immunoblotting with anti-PA serum and HRP-conjugated anti-rabbit secondary antibody.
Treatment with Bacterial Toxins. RAW264.7 cells or BMDMs were preincubated with EGA or derivatives for 1 h followed by intoxication with LT as indicated in figure legends. ATPlite viability reagent (Perkin-Elmer) was added, and relative luminescence was measured as above. For other toxins, HeLa cells were plated at 1 × 10 3 cells per well on each well of a 384-well plate (Greiner). The following day, EGA (Chembridge), NH 4 Cl (Sigma-Aldrich), or bafilomycin A1 (Calbiochem) was added to the indicated concentrations and incubated for 1 h at 37°C. DT was added to a concentration of 5 ng/mL, and ExoA and ricin were added at the indicated concentrations. Cells were incubated for 2 d, and 20 μL of ATPlite were added. Luminescence was measured using the Victor 3 V (Perkin-Elmer). Cell-cycle arrest induced by CDT was measured by propidium iodide staining and flow cytometry as previously described (43) . To monitor subcellular localization of Ec-CdtB or Hd-CdtB, cells were stained and imaged as described (42) with the addition of mouse monoclonal anti-EEA1 antibody (1:50 dilution; Abcam). For each cell, images were collected from an average of 30 z-planes, each at a thickness of 0.2 μm. EEA1-localization analysis was conducted by using the DeltaVision SoftWoRx 3.5.1 software suite. Viral Infections. For transductions with VSV-G and NiV glycoprotein pseudotyped lentiviral vectors or amphotropic and VSV-G pseudotyped MLV vectors, 6.5 × 10 4 cells/mL were seeded in DMEM onto 24-well plates. The following day, the media were removed, and fresh media containing EGA at indicated concentrations or DMSO only were added to cells. Dilutions of pseudotyped viral vectors encoding GFP were added 1 h later with 8 μg/mL polybrene. Cells were incubated overnight, and then virus and drug were removed, followed by another overnight incubation. Cells were then fixed in formaldehyde and analyzed by flow cytometry.
For LCMV infections, plates were seeded at 4 × 10 5 Vero cells/mL and incubated overnight at 37°C. The next day, media were removed, and cells were infected in triplicate at 10 −3 , 10 −4 , and 10 −5 dilution with a trisegmented LCMV Armstrong strain encoding GFP in the presence or absence of 20 μM EGA. The initial stock of LCMV-GFP was 7.3 × 101 h before, simultaneous to, or 1 h after infection with virus. Culture supernatants were collected 10 h post-infection. Gaussia luciferase activity was determined using the Renilla Luciferase Assay System (Promega), and luminescence was measured using the Infinite M1000 plate reader (TECAN). 4 Cl for 15 min at 37°C; and then stimulated with serum-free medium containing the compounds and 100 ng/mL EGF (Gibco) for the indicated time periods. Cells were then washed with cold PBS and lysed in Nonidet P-40 lysis buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 1% Nonidet P-40), and lysates were analyzed by immunoblotting with anti-EGFR 1:2,000 (Santa Cruz, #SC-03), anti-tubulin 1:5,000 (Sigma Aldrich, #T6074-200 μL), anti-p-ERK1/2 pY204 1:1,500 (Epitomics, #2219-1), and anti-ERK1/2 1:5,000 (BD, #610123). Blots were imaged using a Li-Cor Odyssey scanner.
For immunofluorescence microscopy, EGF-Alexa Fluor 647 (Invitrogen, #E35351), anti-EEA1 (BD Transduction Laboratories, #610456), and goatanti-mouse Alexa Fluor 647 (Invitrogen, #A21245) were used. Glass-bottom 35-mm tissue culture plates (MatTek) were seeded with 4 × 10 5 cells. The cells were serum-starved overnight and incubated in medium containing 20 ng/mL EGF-Alexa Flour-647 and 20 μM EGA or DMSO on ice for 2 h. They were then chased for 60 min at 37°C in serum-free medium containing only the compounds and fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton-X-100 detergent, quenched in 50 mM NH 4 . The cells were rinsed in cold serum-free medium and excess unlabeled Tf and chased at 37°C for the indicated amounts of time. Following the chase, the cells were stripped twice in the sodium acetate buffer. Tf-488 fluorescence from acid washes and medium was measured on a Wallac 1420 multilabel counter (PerkinElmer) at a 490/520-nm absorption/emission. Phagocytosis Studies. THP-1 cells were added (1.5 × 10 5 cells/cm 2 ) to poly-Llysine-coated (Sigma-Aldrich) glass coverslips in 2-cm 2 tissue culture wells, differentiated with phorbol 12-myristate 13-acetate (PMA, 100 nM) in RPMI-1640 with 10% (vol/vol) heat-inactivated FBS (HI-FBS) for 3 d at 37°C in 5% CO 2 , and pretreated for 1 h with 250 nm bafilomycin A, 20 μM EGA, or DMSO before addition of bacteria or latex beads. GFP-expressing F. tularensis LVS and escape incompetent GFP-LVS-ΔIglC were prepared and cultured as previously described (63) (64) (65) and added to monolayers of THP-1 cells on glass coverslips in 24-well plates. The plates were centrifuged at 800 × g for 30 min 4°C, incubated at 37°C for 30 min, washed three times with HBSS to remove nonadherent bacteria, and incubated for 3 h at 37°C in fresh RPMI-1640 with 10% (vol/vol) HI-FBS containing 20 μM EGA, 250 nm bafilomycin, or DMSO vehicle. Phagosome integrity was assessed by a modification of the differential digitonin permeabilization method of Checroun et al. (33) , which permeabilizes the plasma membrane but not phagosomal membranes. Briefly, monolayers were fixed for exactly 1 min with HBSS + 4% (vol/ vol) paraformaldehyde followed by permeabilization for exactly 1 min with 0.05 mg/mL digitonin in KHM (110 mM potassium acetate, 20 mM Hepes, pH 7.3, 2 mM MgCl2) with 6% (vol/vol) sucrose, washed twice with KHM containing 6% sucrose, and incubated with rabbit anti-F. tularensis antibody (1:1,000 dilution; Becton Dickinson) in KHM buffer containing 6% sucrose and 0.1% BSA, washed three times with KHM containing 6% sucrose, fixed for 30 min in 4% paraformaldehyde in 75 mM sodium phosphate (pH 7.4), permeabilized in 0.1% saponin in PBS, washed with PBS, and incubated with Texas Red-X conjugated goat anti-rabbit IgG (Invitrogen) for 90 min at room temperature. Monolayers were washed, incubated with DAPI (1 μg/mL), mounted with Prolong Gold anti-fade mounting medium, and viewed by phase and fluorescence microscopy. Green fluorescent bacteria that stain red were scored as having permeabilzed their phagosomes. Escape incompetent GFP-LVS-ΔIglC are inaccessible to antibody after digitonin permeabilization of the plasma membrane and serve as negative controls. At least 400 cells were examined and enumerated in duplicate wells, and the experiments were conducted twice with similar results. Numbers of GFP bacteria per DAPI nucleus under each of the conditions was determined by particle analysis using ImageJ software.
To evaluate the impact of inhibitors on fusion of latex bead phagosomes with secondary lysosomes, we labeled the lysosomal compartments of PMAdifferentiated THP-1 cells with lysine-fixable Texas Red-Dextran (70 kDa, 0.05 mg/mL; Invitrogen) for 12 h. Macrophages were treated with 250 nM bafilomycin A, 20 μM EGA, or DMSO vehicle control for 30 min before uptake of latex beads. Fluorescent blue 1-μm polystyrene microbeads (2.5% solids; Polysciences) were opsonized with human AB serum (66) , diluted 50,000-fold (10 6 particles/mL) in RPMI-1640 with 10% HI-FBS, and added to the monolayers of differentiated THP-1 cells in 24-well plates. After incubation for 3 h at 37°C with vehicle or inhibitors, the macrophages were fixed, stained with DAPI, and mounted as described above. Colocalization of latex beads with Texas Red Dextran fluorescence was assessed by fluorescence and phasecontrast microscopy. At least 40 particles were examined on duplicate coverslips, and the experiments were repeated twice with similar results.
Statistical Analysis. Data were analyzed using GraphPad Prism5 software. Group size, number of replicates, and specific statistical methods used are presented for each experiment in the figure legends.
